Anti-CD19 UCAR-T cells

Developed for: B-cell acute lymphoblastic leukemia · juvenile dermatomyositis
Investigated by: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Central South University · Chongqing Precision Biotech Co., Ltd · First Affiliated Hospital of Kunming Medical University · Fujian Medical University Union Hospital · Gracell Biotechnologies (Shanghai) Co., Ltd.
+8 more
· Nanfang Hospital, Southern Medical University · Second Affiliated Hospital of Xi'an Jiaotong University · Tang-Du Hospital · The Affiliated Hospital Of Guizhou Medical University · The First Affiliated Hospital of Anhui Medical University · The General Hospital of Western Theater Command · The Second Affiliated Hospital of Chongqing Medical University · Xinqiao Hospital of Chongqing

today NCT06686524 · Ph 1 NCT04264039 · Ph 0

2021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT04264039	Apr 2020 → Apr 2021	B-cell acute lymphoblastic leukemia	Xinqiao Hospital of Chongqing	Unknown	No outcome recorded
Phase 11 trial
Phase 1	NCT06686524	Nov 2024 → Nov 2026 expected	juvenile dermatomyositis	Chongqing Precision Biotech Co., Ltd	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	anti-CD19 UCAR-T cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04264039 ↗ 1 NCT06686524 ↗
Modality	Cell therapy	“universal CAR-T cells” NCT04264039 ↗
Route	Intravenous	“administered intravenously” NCT06686524 ↗
Target	CD19	“universal CAR-T cell therapy targeting CD19” NCT06686524 ↗